Daxor - Blood Volume Analysis
Blood Volume Analysis - Guided Heart Failure Management
Sponsor: Daxor Corporation
This NA trial investigates Congestive Heart Failure and Heart Failure and is currently completed. Daxor Corporation leads this study, which shows 14 recorded versions since 2020 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jul 2023 — Jul 2024 [monthly]
Completed NA
-
Jan 2023 — Jul 2023 [monthly]
Completed NA
-
Dec 2022 — Jan 2023 [monthly]
Completed NA
▶ Show 9 earlier versions
-
Oct 2022 — Dec 2022 [monthly]
Completed NA
-
Dec 2021 — Oct 2022 [monthly]
Completed NA
Status: Recruiting → Completed
-
May 2021 — Dec 2021 [monthly]
Recruiting NA
-
Jan 2021 — May 2021 [monthly]
Recruiting NA
-
Sep 2020 — Jan 2021 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jun 2020 — Sep 2020 [monthly]
Not Yet Recruiting NA
-
Mar 2020 — Jun 2020 [monthly]
Not Yet Recruiting NA
-
Feb 2020 — Mar 2020 [monthly]
Not Yet Recruiting NA
-
Nov 2019 — Feb 2020 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Daxor Corporation
- Duke University
For direct contact, visit the study record on ClinicalTrials.gov .